Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5. doi: 10.1073/pnas.1013758107. Epub 2010 Oct 20.

2.

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D.

Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14.

3.

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.

Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, Ledroit M, Hong E, Taha MK, Ellie K, Rajam G, Carlone GM, Claus H, Vogel U, Borrow R, Findlow J, Gilchrist S, Stefanelli P, Fazio C, Carannante A, Oksnes J, Fritzsønn E, Klem AM, Caugant DA, Abad R, Vázquez JA, Rappuoli R, Pizza M, Donnelly JJ, Medini D.

Clin Vaccine Immunol. 2012 Oct;19(10):1609-17. Epub 2012 Aug 8.

4.

A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.

Abad R, Biolchi A, Moschioni M, Giuliani MM, Pizza M, Vázquez JA.

Clin Vaccine Immunol. 2015 Apr;22(4):357-60. doi: 10.1128/CVI.00669-14. Epub 2015 Jan 28.

5.

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R.

Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7.

6.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS.

Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7.

PMID:
20619376
7.

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States.

Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, Carlone G, Medini D.

mSphere. 2017 Nov 15;2(6). pii: e00261-17. doi: 10.1128/mSphere.00261-17. eCollection 2017 Nov-Dec.

8.

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.

Medini D, Stella M, Wassil J.

Vaccine. 2015 May 28;33(23):2629-36. doi: 10.1016/j.vaccine.2015.04.015. Epub 2015 Apr 13. Review.

9.

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.

Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M, Bambini S, Muzzi A, Vázquez JA.

PLoS One. 2016 Mar 7;11(3):e0150721. doi: 10.1371/journal.pone.0150721. eCollection 2016.

10.

Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine.

Claus H, Jördens MS, Kriz P, Musilek M, Jarva H, Pawlik MC, Meri S, Vogel U.

Vaccine. 2012 Jan 5;30(2):155-60. doi: 10.1016/j.vaccine.2011.11.050. Epub 2011 Nov 19.

PMID:
22107847
11.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

12.

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Rossi R, Beernink PT, Giuntini S, Granoff DM.

Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30.

13.

Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.

14.

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R.

Lancet Infect Dis. 2013 May;13(5):416-25. doi: 10.1016/S1473-3099(13)70006-9. Epub 2013 Feb 13.

PMID:
23414709
15.

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D.

J Immunol Res. 2015;2015:353461. doi: 10.1155/2015/353461. Epub 2015 Aug 17. Review.

16.

Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.

Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK.

BMC Microbiol. 2014 Apr 29;14:111. doi: 10.1186/1471-2180-14-111.

17.

High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.

Waśko I, Hong E, De Paola R, Stella M, Moschioni M, Taha MK, Skoczyńska A.

Vaccine. 2016 Jan 20;34(4):510-515. doi: 10.1016/j.vaccine.2015.11.070. Epub 2015 Dec 11.

PMID:
26686998
18.

The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines.

Vogel U, Stefanelli P, Vazquez J, Taha MK, Claus H, Donnelly J.

Vaccine. 2012 May 30;30 Suppl 2:B73-7. doi: 10.1016/j.vaccine.2011.12.061. Review.

PMID:
22607902
19.

Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway.

Holst J, Comanducci M, Bambini S, Muzzi A, Comandi S, Oksnes J, DeTora L, Pizza M, Rappuoli R, Caugant DA.

Vaccine. 2014 May 13;32(23):2722-31. doi: 10.1016/j.vaccine.2014.02.068. Epub 2014 Mar 12.

PMID:
24631075
20.

Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.

Lucidarme J, Gilchrist S, Newbold LS, Gray SJ, Kaczmarski EB, Richardson L, Bennett JS, Maiden MC, Findlow J, Borrow R.

Clin Vaccine Immunol. 2013 Sep;20(9):1360-9. doi: 10.1128/CVI.00090-13. Epub 2013 Jun 26.

Supplemental Content

Support Center